Overview

Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. This is a different patient population than those being assessed in current clinical trials.
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Lenograstim
Loratadine